A carregar...
Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal
INTRODUCTION: In Nepal, adalimumab is the most common agent being used, but in a disease activity-based dose tapering to address the economic constraints. Another constraint is the high risk of reactivation of tuberculosis in countries with high burden, especially with the use of tumor necrosis fact...
Na minha lista:
| Publicado no: | Int J Rheumatol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6463559/ https://ncbi.nlm.nih.gov/pubmed/31057626 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/2034950 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|